What is Zacks Research’s Estimate for STERIS Q3 Earnings?

STERIS plc (NYSE:STE) – Analysts at Zacks Research reduced their Q3 2026 earnings per share (EPS) estimates for STERIS in a research report issued to clients and investors on Tuesday, October 21st. Zacks Research analyst Team now forecasts that the medical equipment provider will post earnings of $2.56 per share for the quarter, down from their previous forecast of $2.57. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.02. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same period in the previous year, the firm earned $2.03 EPS. The business’s revenue was up 8.8% on a year-over-year basis.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Morgan Stanley boosted their price objective on STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, August 8th. KeyCorp lifted their target price on STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Stock Up 0.1%

STERIS stock opened at $242.29 on Wednesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. The company has a market cap of $23.86 billion, a PE ratio of 37.10 and a beta of 1.01. STERIS has a 1-year low of $200.98 and a 1-year high of $253.00. The stock’s 50 day moving average price is $244.96 and its 200 day moving average price is $236.71.

STERIS Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 26th. Stockholders of record on Thursday, September 4th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, September 4th. This is an increase from STERIS’s previous quarterly dividend of $0.57. STERIS’s dividend payout ratio (DPR) is presently 38.59%.

Insiders Place Their Bets

In related news, Director Cynthia L. Feldmann sold 3,495 shares of the firm’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.56, for a total value of $844,252.20. Following the completion of the sale, the director owned 705 shares in the company, valued at $170,299.80. This trade represents a 83.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mohsen Sohi sold 4,110 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.96, for a total value of $994,455.60. Following the transaction, the director owned 22,361 shares in the company, valued at $5,410,467.56. This trade represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 18,868 shares of company stock valued at $4,585,389. 1.07% of the stock is owned by insiders.

Institutional Trading of STERIS

Several institutional investors have recently added to or reduced their stakes in STE. Cerity Partners LLC boosted its stake in STERIS by 28.8% during the 3rd quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock valued at $23,966,000 after purchasing an additional 21,656 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in STERIS by 6.8% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 5,843 shares of the medical equipment provider’s stock worth $1,446,000 after purchasing an additional 370 shares in the last quarter. Harvey Investment Co. LLC boosted its position in STERIS by 17.1% during the 3rd quarter. Harvey Investment Co. LLC now owns 93,105 shares of the medical equipment provider’s stock worth $23,038,000 after acquiring an additional 13,580 shares during the period. Asset Management One Co. Ltd. boosted its holdings in shares of STERIS by 5.4% during the third quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock worth $24,366,000 after purchasing an additional 5,072 shares during the period. Finally, Fifth Third Wealth Advisors LLC purchased a new position in shares of STERIS during the 3rd quarter valued at $615,000. Institutional investors own 94.69% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.